Oramed Pharmaceuticals Inc.
ORMP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 8/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $1,340 | $2,703 | $2,703 |
| % Growth | -100% | -50.4% | 0% | – |
| Cost of Goods Sold | $193 | $0 | $0 | $0 |
| Gross Profit | -$193 | $1,340 | $2,703 | $2,703 |
| % Margin | – | 100% | 100% | 100% |
| R&D Expenses | $6,324 | $8,971 | $27,639 | $20,989 |
| G&A Expenses | $6,457 | $8,425 | $13,811 | $5,937 |
| SG&A Expenses | $6,457 | $8,138 | $15,662 | $5,937 |
| Sales & Mktg Exp. | $0 | -$287 | $1,851 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $12,781 | $17,109 | $43,301 | $26,926 |
| Operating Income | -$12,781 | -$15,769 | -$40,598 | -$24,223 |
| % Margin | – | -1,176.8% | -1,502% | -896.2% |
| Other Income/Exp. Net | -$3,139 | $20,857 | $2,934 | $893 |
| Pre-Tax Income | -$15,920 | $5,088 | -$37,664 | -$22,989 |
| Tax Expense | $3,183 | $0 | $100 | -$2,878 |
| Net Income | -$19,103 | $5,525 | -$37,764 | -$22,238 |
| % Margin | – | 412.3% | -1,397.1% | -822.7% |
| EPS | -0.47 | 0.14 | -0.97 | -0.78 |
| % Growth | -435.7% | 114.4% | -24.4% | – |
| EPS Diluted | -0.47 | 0.14 | -0.97 | -0.78 |
| Weighted Avg Shares Out | 40,828 | 40,315 | 38,998 | 28,469 |
| Weighted Avg Shares Out Dil | 40,828 | 40,567 | 38,998 | 28,469 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $8,026 | $3,573 | $347 |
| Interest Expense | $853 | $3,580 | $0 | $6 |
| Depreciation & Amortization | $193 | $196 | $3,622 | $77 |
| EBITDA | -$14,874 | $7,321 | -$36,976 | -$25,039 |
| % Margin | – | 546.3% | -1,368% | -926.3% |